Compare DexCom, Inc. (DXCM) vs Sirius XM Holdings Inc (SIRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Sirius XM Holdings Inc — how do they compare? DexCom, Inc. trades at $78.49 (market cap $28.06B), while Sirius XM Holdings Inc trades at $31.3 (market cap $10.32B). The key difference: DexCom, Inc. is far larger — about 2.7× Sirius XM Holdings Inc's market cap, and Sirius XM Holdings Inc pays a 3.52% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | SIRI | |
|---|---|---|
Market Cap | $28.06B | $10.32B |
Sector | Health | Media |
52-Week High | $89.53 | $30.75 |
52-Week Low | $54.84 | $19.92 |
Enterprise Value | $27.03B | $19.99B |
Dividend Yield | — | 3.52% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
Sirius XM Holdings (SIRI) trades at $30.39, down 0.91% on the day, with strong technical momentum indicated by bullish moving averages. The company has beaten earnings expectations for three consecutive quarters, with Q2 2026 results due July 30. Recent developments include a strategic ad tech partnership with YouTube and potential inclusion in the S&P MidCap 400, driving positive investor sentiment.
The outlook remains positive with analyst consensus at Buy (58%) and $31.17 price target. Strong cash flow generation supports dividends and buybacks, though high debt levels and competitive pressures in media streaming present ongoing risks. Recent return to profitability after 2024's net loss positions SIRI for sustained growth if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Sirius XM Holdings Inc
SiriusXM Holdings is now composed of two businesses: SiriusXM and Pandora. SiriusXM transmits music, talk shows, sports, and news via its two satellite radio networks, primarily to consumers in vehicles who pay a subscription fee. The firm's radios come preinstalled on a wide range of light vehicles in the U.S. and Canada. The firm acquired Pandora Media in February 2019 via an all-stock transaction. Pandora is a streaming music platform that offers an ad-supported radio option and a paid on-demand service. Liberty Media owns 80% of SiriusXM, traded through its Liberty SiriusXM Group tracking stock.
Read more on SIRI →
